The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women

Climacteric

Volumn 10, Issue 5, 2007, Pages 400-407

  Keramaris, N C ^a   Christodoulakos, G E ^b   Lambrinoudaki, I V ^b,c   Dalamanga, A ^b   Alexandrou, A P ^a   Bramis, J ^a   Bastounis, E ^a   Creatsas, G C ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c Hippocrateion Hospital ^*  (Greece)

Author keywords

Antithrombin; Conjugated equine estrogens; Estradiol; Hormone therapy; Protein C; Protein S; Tibolone

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING INHIBITOR; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PROTEIN C; PROTEIN S; TIBOLONE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTRADIOL CONGENERS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FIBRINOLYSIS; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NORETHINDRONE; NORPREGNENES; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 34548648707     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701624773     Document Type: Article

References (35)

1. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37
2. Skouby S, Al-Azzawi F, Barlow D, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 2005;51:8-14
3. Gambacciani M, Monteleone P, Genazzani AR. Low-dose hormone replacement therapy: effects on bone. Climacteric 2002;5:135-9
4. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34
5. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. HERS Research Group. JAMA 1998;280:605-13
6. Daly E, Vessey MP, Hawkins MN, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-80
7. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of post-menopausal oestrogens. Lancet 1996;348:981-3
8. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000;343:522-9
9. The Writing Group for The Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33
10. Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US Preventive Services Task Force. Ann Intern Med 2002;136:680-90
11. Winkler UH. Hormone replacement therapy and hemostasis: principles of a complex interaction. Maturitas 1996;24:131-45
12. Winkler UH. The effects of progestins on cardiovascular system: the haemostatic system. Hum Reprod Update 1999;5:200-4
13. Kwang Kon Koh, Jeong Yeal Ahn, Jin DK, et al. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study. Arterioscler Thromb Vasc Biol 2003;23:1889-94
14. Castelo-Branco C, Garcia-Fantini M, Haya J. Vascular reactivity and atheromatous plaques in post-menopausal women on tibolone treatment. Open prospective study with Doppler ultrasonography in internal carotid artery. Maturitas 2005;50:259-65
15. Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005;51:21-8
16. Meilahn E, Kuller LH, Lambrinoudaki IV, et al. Coagulation parameters among pre- and post-menopausal women. Am J Epidemiol 1988;28:908
17. Meade TW, Dyer S, Howarth DJ, Imeson JD, Stirling Y. Antithrombin III and procoagulant activity: sex differences and effects of menopause. Br J Haematol 1990;74:77-81
18. Cosman F, Baz-Hechtc M, Cushman M, et al. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. Thromb Res 2005;116:1-13
19. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in post-menopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
20. Gilabert J, Estelles A, Cano A, et al. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Am J Obstet Gynecol 1995;173:1849-54
21. Osmanagaoglu MA, Osmanagaoglu S, Osmanagaoglu T, Okumus B, Bozkaya H. Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women. Fertil Steril 2005;84:384-93
22. Gottsater A, Rendell M, Hulthen UL, Berntorp E, Mattiasson I. Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors. J Intern Med 2001;249:237-4
23. Kessler CM, Szymanski LM, Shamsipour Z, Muesing RA, Miller VT, LaRosa JC. Estrogen replacement therapy and coagulation: relationship to lipid and lipoprotein changes. Obstet Gynecol 1997;89:326-31
24. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in post-menopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
25. Tikkanen MJ. The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors. Maturitas 1996;23:209-16
26. Koh KK, Yoon BK. Controversies regarding hormone therapy: insights from inflammation and hemostasis. Cardiovasc Res 2006;70:22-30
27. Bjarnason NH, Bjarnason K, Haarbo J, Coelingh Bennink HJT, Christiansen C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997;82:1752-6
28. Rosati D, Micheli S, Pinto S, et al. Changes in lipidic and hemostatic parameters induced by tibolone treatment. Thromb Res 1997;85:273-8
29. Winkler UH, Altkemper R, Kwee B, Helmond FA, Coelingh Bennink HJT. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 2000;74:10-19
30. Skouby SO, Sidelmann JJ, Nilas L, Jespersen J. A comparative study on the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coaguability. Hum Reprod 2007;22:1186-91
31. Winkler UH. Effects of androgens on haemostasis. Maturitas 1996;24:147-55
32. Preston FE, Burakowski BK, Porter NR, Malia RG. The fibrinolytic response to stanozolol in normal subjects. Thromb Res 1981;22:543-51
33. Bots ML, Evans GW, Riley W, et al. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur Heart J 2006;27:746-55
34. Cummings SR. LIFT study is discontinued. BMJ 2006;332:667
35. Braunstein JB, Kershner DW, Bray P, et al. Interaction of hemostatic genetics with hormone therapy: new insights to explain arterial thrombosis in postmenopausal women. Chest 2002;121:906-19